Portfoliotracker

Evolus, Inc.

EOLS · NASDAQGM · Healthcare Drug Manufacturers - Specialty & Generic 3/100 E

6,630 $
▼ −0,330 (−4,74 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:30
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score3 / 100 Market cap438 mil. $ P/E– Forward P/E23,3 P/S1,3 P/B– EV/EBITDA– Dividend yield– FCF yield-1,12 % EPS-0,48 $ Net margin-9,6 % Return on equity– Beta1,34 Debt / equity–
52-week range 3,86 to 9,31
3-month average volume0,9 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Website
evolus.com
Employees
365
Country
United States
Fiscal year end
31. 12.
Data since
8. 2. 2018

Explore further

Similar companies SLDBANABMGNXCOLLACRS

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account